Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 8/20 | 0.41 |
| ▸ | DPP4 | P27487 | 6/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.41 |
| ▸ | PREP | P48147 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 3/20 | 0.39 |
| ▸ | FAP | Q12884 | 2/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.37 |
| ▸ | XIAP | P98170 | 1/20 | 0.35 |
| ▸ | REN | P00797 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21575909 | 0.92 | CAPN1 (0.41) | CAPN1DPP4DPP7PREPCTSB | |
| SCHEMBL22148189 | 0.81 | DPP4 (0.40) | CAPN1DPP4DPP7PREPCTSB | |
| SCHEMBL24222578 | 0.77 | CAPN1 (0.46) | CAPN1DPP4DPP7PREPCTSB | |
| SCHEMBL21103618 | 0.77 | CAPN1 (0.46) | CAPN1DPP4DPP7PREPCTSB | |
| SCHEMBL20693249 | 0.77 | CAPN1 (0.46) | CAPN1DPP4DPP7PREPCTSB | |
| SCHEMBL28478640 | 0.76 | CAPN1 (0.53) | CAPN1DPP4DPP7PREPCTSB | |
| SCHEMBL28478644 | 0.76 | CAPN1 (0.53) | CAPN1DPP4DPP7PREPCTSB | |
| Rapastinel SCHEMBL23859842 | 0.73 | CAPN1 (0.59) | CAPN1DPP4DPP7PREPCTSB | |
| Rapastinel SCHEMBL23859841 | 0.73 | CAPN1 (0.59) | CAPN1DPP4DPP7PREPCTSB | |
| Rapastinel SCHEMBL25266713 | 0.73 | CAPN1 (0.59) | CAPN1DPP4DPP7PREPCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200368310-A1 | TREATMENT WITH NMDA RECEPTOR MODULATORS | INNOVIVA TRC HOLDINGS LLC | 2020-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200368310-A1 | TREATMENT WITH NMDA RECEPTOR MODULATORS | GRIN2A, GRIN1, GRIN2B | CAPN1 1148/4885DPP4 2825/4885DPP7 2827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.